{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:12:55Z","timestamp":1793049175858,"version":"4.5.0"},"reference-count":91,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P50CA221747"],"award-info":[{"award-number":["P50CA221747"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Von Hippel-Lindau (VHL) disease is a tumor predisposition syndrome caused by mutations in the VHL gene that presents with visceral neoplasms and growths, including clear cell renal cell carcinoma, and central nervous system manifestations, such as hemangioblastomas of the brain and spine. The pathophysiology involves dysregulation of oxygen sensing caused by the inability to degrade HIF\u03b1, leading to the overactivation of hypoxic pathways. Hemangioblastomas are the most common tumors in patients with VHL and cause significant morbidity. Until recently, there were no systemic therapies available for patients that could effectively reduce the size of these lesions. Belzutifan, the first approved HIF-2\u03b1 inhibitor, has demonstrated benefit in VHL-associated tumors, with a 30% response rate in hemangioblastomas and ~30%\u201350% reduction in their sizes over the course of treatment. Anemia is the most prominent adverse effect, affecting 76%\u201390% of participants and sometimes requiring dose reduction or transfusion. Other significant adverse events include hypoxia and fatigue. Overall, belzutifan is well tolerated; however, long-term data on dosing regimens, safety, and fertility are not yet available. Belzutifan holds promise for the treatment of neurological manifestations of VHL and its utility may influence the clinical management paradigms for this patient population.<\/jats:p>","DOI":"10.1093\/neuonc\/noac234","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T20:34:32Z","timestamp":1665434072000},"page":"827-838","source":"Crossref","is-referenced-by-count":24,"title":["Neurological applications of belzutifan in von Hippel-Lindau disease"],"prefix":"10.1093","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3148-8833","authenticated-orcid":false,"given":"Yue","family":"Zhang","sequence":"first","affiliation":[{"name":"Northwestern University, Feinberg School of Medicine , 420 E Superior St. Chicago, IL 60611 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3109-134X","authenticated-orcid":false,"given":"Catherine C","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Loyola University , Chicago, IL, 60660 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5873-2755","authenticated-orcid":false,"given":"Nigel T","family":"Zhang","sequence":"additional","affiliation":[{"name":"Northwestern University, Feinberg School of Medicine , 420 E Superior St. Chicago, IL 60611 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0860-5085","authenticated-orcid":false,"given":"Nicolas S","family":"Fink","sequence":"additional","affiliation":[{"name":"Northwestern University, Feinberg School of Medicine , 420 E Superior St. Chicago, IL 60611 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4981-5748","authenticated-orcid":false,"given":"Jordan D","family":"John","sequence":"additional","affiliation":[{"name":"Northwestern University, Feinberg School of Medicine , 420 E Superior St. Chicago, IL 60611 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0596-5824","authenticated-orcid":false,"given":"Omkar G","family":"Venkatesh","sequence":"additional","affiliation":[{"name":"Northwestern University, Feinberg School of Medicine , 420 E Superior St. Chicago, IL 60611 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5715-2692","authenticated-orcid":false,"given":"Jonathan D","family":"Roe","sequence":"additional","affiliation":[{"name":"Northwestern University, Feinberg School of Medicine , 420 E Superior St. Chicago, IL 60611 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1191-7263","authenticated-orcid":false,"given":"Steven C","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Northwestern University, Feinberg School of Medicine , 420 E Superior St. Chicago, IL 60611 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0096-5107","authenticated-orcid":false,"given":"Maciej S","family":"Lesniak","sequence":"additional","affiliation":[{"name":"Lou & Jean Malnati Brain Tumor Institute , Chicago, Illinois 60611 , USA"},{"name":"Department of Neurological Surgery, Northwestern University , Chicago, Illinois 60611 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5599-4143","authenticated-orcid":false,"given":"Jean-Paul","family":"Wolinsky","sequence":"additional","affiliation":[{"name":"Lou & Jean Malnati Brain Tumor Institute , Chicago, Illinois 60611 , USA"},{"name":"Department of Neurological Surgery, Northwestern University , Chicago, Illinois 60611 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8340-9992","authenticated-orcid":false,"given":"Craig","family":"Horbinski","sequence":"additional","affiliation":[{"name":"Lou & Jean Malnati Brain Tumor Institute , Chicago, Illinois 60611 , USA"},{"name":"Department of Neurological Surgery, Northwestern University , Chicago, Illinois 60611 , USA"},{"name":"Department of Pathology, Northwestern University , Chicago, Illinois 60611 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany M","family":"Szymaniak","sequence":"additional","affiliation":[{"name":"Department of Urology, Northwestern University , Chicago, Illinois 60611 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8808-4020","authenticated-orcid":false,"given":"Robin A","family":"Buerki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Northwestern University , Chicago, Illinois 60611 , USA"},{"name":"Lou & Jean Malnati Brain Tumor Institute , Chicago, Illinois 60611 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0650-9698","authenticated-orcid":false,"given":"Jeffrey A","family":"Sosman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology and Oncology, Northwestern University , Chicago, Illinois 60611 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2074-1108","authenticated-orcid":false,"given":"Niraj K","family":"Shenoy","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology and Oncology, Northwestern University , Chicago, Illinois 60611 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4115-6370","authenticated-orcid":false,"given":"Rimas V","family":"Lukas","sequence":"additional","affiliation":[{"name":"Department of Neurology, Northwestern University , Chicago, Illinois 60611 , USA"},{"name":"Lou & Jean Malnati Brain Tumor Institute , Chicago, Illinois 60611 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,10]]},"reference":[{"issue":"22","key":"2023050411190401900_CIT0001","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel-Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med."},{"issue":"141","key":"2023050411190401900_CIT0002","first-page":"1894","article-title":"Intra-ocular growths (two cases, brother and sister, with peculiar vascular new growth, probably retinal, affecting both eyes)","volume":"14","author":"Collins","year":"1894","journal-title":"Trans Ophthalmol Soc UK."},{"key":"2023050411190401900_CIT0003","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/BF01994821","article-title":"\u00dcber eine sehr seltene Erkrankung der Netzhaut","volume":"(59)","author":"Hippel","year":"1904","journal-title":"Graefes Archiv Clin Exp Ophthalmol."},{"issue":"1-2","key":"2023050411190401900_CIT0004","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1755-3768.1926.tb07786.x","article-title":"Zur frage der angiomatosis retinae und ihrer hirnkomplikationen","volume":"4","author":"Lindau","year":"1926","journal-title":"Acta Ophthalmol."},{"issue":"5112","key":"2023050411190401900_CIT0005","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.8493574","article-title":"Identification of the von Hippel-Lindau disease tumor suppressor gene","volume":"260","author":"Latif","year":"1993","journal-title":"Science."},{"issue":"5","key":"2023050411190401900_CIT0006","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamaneurol.2017.4469","article-title":"Review of the neurological implications of von Hippel-Lindau disease","volume":"75","author":"Dornbos","year":"2018","journal-title":"JAMA Neurol."},{"issue":"33","key":"2023050411190401900_CIT0007","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.2174\/138161209789649394","article-title":"The VHL tumor suppressor: master regulator of HIF","volume":"15","author":"Haase","year":"2009","journal-title":"Curr Pharm Des."},{"issue":"2","key":"2023050411190401900_CIT0008","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/jmg.33.2.120","article-title":"A genetic register for von Hippel-Lindau disease","volume":"33","author":"Maddock","year":"1996","journal-title":"J Med Genet."},{"issue":"4","key":"2023050411190401900_CIT0009","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/jhg.2012.10","article-title":"Family history of von Hippel-Lindau disease was uncommon in Chinese patients: suggesting the higher frequency of de novo mutations in VHL gene in these patients","volume":"57","author":"Wu","year":"2012","journal-title":"J Hum Genet."},{"issue":"3","key":"2023050411190401900_CIT0010","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/106689690000800308","article-title":"Allelic deletion of VHL gene detected in papillary tumors of the broad ligament, epididymis, and retroperitoneum in von hippel-lindau disease patients","volume":"8","author":"Shen","year":"2000","journal-title":"Int J Surg Pathol."},{"issue":"6","key":"2023050411190401900_CIT0011","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ejhg.2010.175","article-title":"von Hippel-Lindau disease: a clinical and scientific review","volume":"19","author":"Maher","year":"2011","journal-title":"Eur J Hum Genet."},{"issue":"9374","key":"2023050411190401900_CIT0012","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(03)13643-4","article-title":"von Hippel-Lindau disease","volume":"361","author":"Lonser","year":"2003","journal-title":"Lancet."},{"issue":"283","key":"2023050411190401900_CIT0013","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/qjmed\/77.2.1151","article-title":"Clinical features and natural history of von Hippel-Lindau disease","volume":"77","author":"Maher","year":"1990","journal-title":"Q J Med."},{"issue":"4","key":"2023050411190401900_CIT0014","doi-asserted-by":"crossref","first-page":"46","DOI":"10.15586\/jkcvhl.2014.12","article-title":"Pathological and clinical features and management of central nervous system Hemangioblastomas in von Hippel-Lindau disease","volume":"1","author":"Kanno","year":"2014","journal-title":"J Kidney Cancer VHL."},{"issue":"1","key":"2023050411190401900_CIT0015","first-page":"78","article-title":"Von Hippel-Lindau disease and the eye","volume":"15","author":"Karimi","year":"2020","journal-title":"J Ophthalmic Vis Res."},{"issue":"9","key":"2023050411190401900_CIT0016","first-page":"3067","article-title":"Retinal hemangioblastoma in von Hippel-Lindau disease: a clinical and molecular study","volume":"43","author":"Dollfus","year":"2002","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"12","key":"2023050411190401900_CIT0017","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1097\/IAE.0000000000002572","article-title":"Management of retinal hemangioblastoma in von Hippel-Lindau disease","volume":"39","author":"Wiley","year":"2019","journal-title":"Retina."},{"issue":"2","key":"2023050411190401900_CIT0018","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/humu.20385","article-title":"Genotype-phenotype correlations in von Hippel-Lindau disease","volume":"28","author":"Ong","year":"2007","journal-title":"Hum Mutat."},{"issue":"5","key":"2023050411190401900_CIT0019","first-page":"4600","article-title":"Distinctive clinicopathological features of Von Hippel-Lindau-associated hereditary renal cell carcinoma: a single-institution study","volume":"17","author":"Hong","year":"2019","journal-title":"Oncol Lett."},{"issue":"1","key":"2023050411190401900_CIT0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/jmedgenet-2016-104058","article-title":"Survival and causes of death in patients with von Hippel-Lindau disease","volume":"54","author":"Binderup","year":"2017","journal-title":"J Med Genet."},{"key":"2023050411190401900_CIT0021","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.3389\/fonc.2019.01037","article-title":"Hemangioblastoma instead of renal cell carcinoma plays a major role in the unfavorable overall survival of von Hippel-Lindau disease patients","volume":"9","author":"Zhou","year":"2019","journal-title":"Front Oncol."},{"issue":"3","key":"2023050411190401900_CIT0022","doi-asserted-by":"crossref","first-page":"20","DOI":"10.15586\/jkcvhl.2017.88","article-title":"A review of Von Hippel-Lindau syndrome","volume":"4","author":"Varshney","year":"2017","journal-title":"J Kidney Cancer VHL."},{"issue":"6","key":"2023050411190401900_CIT0023","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.str.2017.04.009","article-title":"Crystal structure of the Cul2-Rbx1-EloBC-VHL Ubiquitin Ligase complex","volume":"25","author":"Cardote","year":"2017","journal-title":"Structure."},{"issue":"5516","key":"2023050411190401900_CIT0024","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1126\/science.1059817","article-title":"HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing","volume":"292","author":"Ivan","year":"2001","journal-title":"Science."},{"issue":"4","key":"2023050411190401900_CIT0025","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2008.04.009","article-title":"Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway","volume":"30","author":"Kaelin","year":"2008","journal-title":"Mol Cell."},{"issue":"6733","key":"2023050411190401900_CIT0026","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis","volume":"399","author":"Maxwell","year":"1999","journal-title":"Nature."},{"issue":"7","key":"2023050411190401900_CIT0027","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/35017054","article-title":"Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein","volume":"2","author":"Ohh","year":"2000","journal-title":"Nat Cell Biol."},{"issue":"3","key":"2023050411190401900_CIT0028","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","article-title":"Hypoxia-inducible factors in physiology and medicine","volume":"148","author":"Semenza","year":"2012","journal-title":"Cell."},{"issue":"9","key":"2023050411190401900_CIT0029","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1073\/pnas.90.9.4304","article-title":"General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia","volume":"90","author":"Wang","year":"1993","journal-title":"Proc Natl Acad Sci USA."},{"issue":"29","key":"2023050411190401900_CIT0030","doi-asserted-by":"crossref","first-page":"21513","DOI":"10.1016\/S0021-9258(20)80571-7","article-title":"Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia","volume":"268","author":"Wang","year":"1993","journal-title":"J Biol Chem."},{"issue":"11","key":"2023050411190401900_CIT0031","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nrc2502","article-title":"The von Hippel-Lindau tumour suppressor protein: o2 sensing and cancer","volume":"8","author":"Kaelin","year":"2008","journal-title":"Nat Rev Cancer."},{"issue":"9","key":"2023050411190401900_CIT0032","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/annonc\/mdw241","article-title":"Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective","volume":"27","author":"Shenoy","year":"2016","journal-title":"Ann Oncol."},{"issue":"6","key":"2023050411190401900_CIT0033","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ccr.2008.10.016","article-title":"HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma","volume":"14","author":"Gordan","year":"2008","journal-title":"Cancer Cell."},{"issue":"3","key":"2023050411190401900_CIT0034","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S1535-6108(02)00043-0","article-title":"Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein","volume":"1","author":"Kondo","year":"2002","journal-title":"Cancer Cell."},{"issue":"13","key":"2023050411190401900_CIT0035","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1128\/MCB.25.13.5675-5686.2005","article-title":"Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma","volume":"25","author":"Raval","year":"2005","journal-title":"Mol Cell Biol."},{"issue":"10","key":"2023050411190401900_CIT0036","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrc1187","article-title":"Targeting HIF-1 for cancer therapy","volume":"3","author":"Semenza","year":"2003","journal-title":"Nat Rev Cancer."},{"issue":"5","key":"2023050411190401900_CIT0037","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/onc.2009.441","article-title":"Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics","volume":"29","author":"Semenza","year":"2010","journal-title":"Oncogene."},{"issue":"1","key":"2023050411190401900_CIT0038","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1038\/s41467-020-17873-3","article-title":"HIF-1\u03b1 and HIF-2\u03b1 differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice","volume":"11","author":"Hoefflin","year":"2020","journal-title":"Nat Commun."},{"issue":"3","key":"2023050411190401900_CIT0039","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1535-6108(02)00044-2","article-title":"The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma","volume":"1","author":"Maranchie","year":"2002","journal-title":"Cancer Cell."},{"issue":"3","key":"2023050411190401900_CIT0040","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1158\/2159-8290.CD-11-0098","article-title":"Genetic and functional studies implicate HIF1\u03b1 as a 14q kidney cancer suppressor gene","volume":"1","author":"Shen","year":"2011","journal-title":"Cancer Discov."},{"issue":"1","key":"2023050411190401900_CIT0041","doi-asserted-by":"crossref","first-page":"17642","DOI":"10.1038\/s41598-020-74631-7","article-title":"HIF1\u03b1 is not a target of 14q deletion in clear cell renal cancer","volume":"10","author":"Shenoy","year":"2020","journal-title":"Sci Rep."},{"issue":"9","key":"2023050411190401900_CIT0042","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1128\/MCB.26.9.3514-3526.2006","article-title":"Differential regulation of the transcriptional activities of hypoxia-inducible factor 1 alpha (HIF-1alpha) and HIF-2alpha in stem cells","volume":"26","author":"Hu","year":"2006","journal-title":"Mol Cell Biol."},{"issue":"24","key":"2023050411190401900_CIT0043","doi-asserted-by":"crossref","first-page":"9361","DOI":"10.1128\/MCB.23.24.9361-9374.2003","article-title":"Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation","volume":"23","author":"Hu","year":"2003","journal-title":"Mol Cell Biol."},{"issue":"25","key":"2023050411190401900_CIT0044","doi-asserted-by":"crossref","first-page":"16767","DOI":"10.1074\/jbc.M901790200","article-title":"Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts","volume":"284","author":"Mole","year":"2009","journal-title":"J Biol Chem."},{"issue":"23","key":"2023050411190401900_CIT0045","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1182\/blood-2010-10-314427","article-title":"High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq","volume":"117","author":"Sch\u00f6del","year":"2011","journal-title":"Blood."},{"issue":"6","key":"2023050411190401900_CIT0046","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1097\/00005072-199511000-00011","article-title":"High expression of the Glut1 glucose transporter in human brain hemangioblastoma endothelium","volume":"54","author":"Cornford","year":"1995","journal-title":"J Neuropathol Exp Neurol."},{"issue":"1","key":"2023050411190401900_CIT0047","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0002-9440(10)65541-1","article-title":"Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF\/HIF-2alpha","volume":"153","author":"Flamme","year":"1998","journal-title":"Am J Pathol."},{"issue":"48","key":"2023050411190401900_CIT0048","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1038\/sj.onc.1203938","article-title":"Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function","volume":"19","author":"Krieg","year":"2000","journal-title":"Oncogene."},{"issue":"14","key":"2023050411190401900_CIT0049","doi-asserted-by":"crossref","first-page":"6178","DOI":"10.1158\/0008-5472.CAN-04-4406","article-title":"Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor","volume":"65","author":"Zagzag","year":"2005","journal-title":"Cancer Res."},{"issue":"7","key":"2023050411190401900_CIT0050","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.ymthe.2018.05.004","article-title":"Differential but complementary HIF1\u03b1 and HIF2\u03b1 transcriptional regulation","volume":"26","author":"Downes","year":"2018","journal-title":"Mol Ther."},{"issue":"6","key":"2023050411190401900_CIT0051","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3340\/jkns.2007.42.6.436","article-title":"Spinal cord hemangioblastoma: diagnosis and clinical outcome after surgical treatment","volume":"42","author":"Na","year":"2007","journal-title":"J Korean Neurosurg Soc."},{"issue":"10","key":"2023050411190401900_CIT0052","first-page":"853","article-title":"Posterior fossa hemangioblastomas","volume":"22","author":"Gelabert\u00a0Gonz\u00e1lez","year":"2007","journal-title":"Neurologia."},{"issue":"1","key":"2023050411190401900_CIT0053","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3171\/jns.2003.98.1.0095","article-title":"Surgical management of brainstem hemangioblastomas in patients with von Hippel-Lindau disease","volume":"98","author":"Weil","year":"2003","journal-title":"J Neurosurg."},{"issue":"23","key":"2023050411190401900_CIT0054","doi-asserted-by":"crossref","first-page":"10847","DOI":"10.1158\/0008-5472.CAN-05-1104","article-title":"Effects of VHL deficiency\u00a0on\u00a0endolymphatic duct and sac","volume":"65","author":"Gl\u00e4sker","year":"2005","journal-title":"Cancer Res."},{"issue":"6","key":"2023050411190401900_CIT0055","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3171\/spi.2005.3.6.0495","article-title":"Spinal hemangioblastoma containing metastatic renal cell carcinoma in von Hippel-Lindau disease. Case report and review of the literature","volume":"3","author":"Altinoz","year":"2005","journal-title":"J Neurosurg Spine."},{"issue":"4","key":"2023050411190401900_CIT0056","doi-asserted-by":"crossref","first-page":"641","DOI":"10.5858\/2007-131-641-MRCCTH","article-title":"Metastatic renal cell carcinoma to hemangioblastoma in von Hippel-Lindau disease","volume":"131","author":"Polydorides","year":"2007","journal-title":"Arch Pathol Lab Med."},{"issue":"6","key":"2023050411190401900_CIT0057","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1148\/rg.336125110","article-title":"Metastatic renal cell carcinoma: radiologic findings and assessment of response to targeted antiangiogenic therapy by using multidetector CT","volume":"33","author":"Brufau","year":"2013","journal-title":"Radiographics."},{"issue":"6","key":"2023050411190401900_CIT0058","doi-asserted-by":"crossref","first-page":"e1163","DOI":"10.1016\/j.clgc.2019.08.006","article-title":"Brain metastasis from renal-cell carcinoma: an institutional study","volume":"17","author":"Suarez-Sarmiento","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"2023050411190401900_CIT0059","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.juro.2009.02.128","article-title":"Metastatic renal cell carcinoma risk according to tumor size","volume":"182","author":"Thompson","year":"2009","journal-title":"J Urol."},{"key":"2023050411190401900_CIT0060","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.clineuro.2014.11.002","article-title":"Using DynaCT rotational angiography for angioarchitecture evaluation and complication detection in spinal vascular diseases","volume":"128","author":"Li","year":"2015","journal-title":"Clin Neurol Neurosurg."},{"key":"2023050411190401900_CIT0061","article-title":"Hemangioblastoma diagnosis and surveillance in von Hippel-Lindau disease: a consensus statement","volume":"136(6):1511\u20131516","author":"Huntoon","year":"2021","journal-title":"J Neurosurg."},{"issue":"1","key":"2023050411190401900_CIT0062","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11060-019-03213-z","article-title":"Growth rate and fate of untreated hemangioblastomas: clinical assessment of the experience of a single institution","volume":"144","author":"Byun","year":"2019","journal-title":"J Neurooncol."},{"issue":"5","key":"2023050411190401900_CIT0063","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.3171\/2014.1.JNS131431","article-title":"Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease","volume":"120","author":"Lonser","year":"2014","journal-title":"J Neurosurg."},{"issue":"3","key":"2023050411190401900_CIT0064","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/ki.1996.395","article-title":"Renal involvement in von Hippel-Lindau disease","volume":"50","author":"Chauveau","year":"1996","journal-title":"Kidney Int."},{"issue":"2","key":"2023050411190401900_CIT0065","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0377-1237(06)80067-5","article-title":"Anaesthetic implication of Von Hippel Lindau disease","volume":"62","author":"Murthy","year":"2006","journal-title":"Med J Armed Forces India."},{"issue":"5","key":"2023050411190401900_CIT0066","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/NRL.0000000000000085","article-title":"Neurological management of Von Hippel-Lindau disease","volume":"21","author":"Hodgson","year":"2016","journal-title":"Neurologist."},{"issue":"2","key":"2023050411190401900_CIT0067","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s10143-020-01305-3","article-title":"Safety and efficacy of surgical treatment for brainstem hemangioblastoma: a meta-analysis","volume":"44","author":"Yin","year":"2021","journal-title":"Neurosurg Rev."},{"key":"2023050411190401900_CIT0068","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jocn.2016.03.008","article-title":"Gamma Knife radiosurgery for intracranial hemangioblastoma","volume":"31","author":"Silva","year":"2016","journal-title":"J Clin Neurosci."},{"issue":"2","key":"2023050411190401900_CIT0069","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3171\/jns.2006.105.2.248","article-title":"Long-term natural history of hemangioblastomas in patients with von Hippel-Lindau disease: implications for treatment","volume":"105","author":"Ammerman","year":"2006","journal-title":"J Neurosurg."},{"issue":"1","key":"2023050411190401900_CIT0070","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11060-017-2697-0","article-title":"Stereotactic radiosurgery for central nervous system hemangioblastoma: systematic review and meta-analysis","volume":"137","author":"Pan","year":"2018","journal-title":"J Neurooncol."},{"key":"2023050411190401900_CIT0071","doi-asserted-by":"crossref","first-page":"105912","DOI":"10.1016\/j.clineuro.2020.105912","article-title":"Stereotactic radiosurgery for central nervous system hemangioblastoma in von Hippel-Lindau disease: a systematic review and meta-analysis","volume":"195","author":"Qiu","year":"2020","journal-title":"Clin Neurol Neurosurg."},{"issue":"1","key":"2023050411190401900_CIT0072","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/neuonc\/nop018","article-title":"Prospective evaluation of radiosurgery for hemangioblastomas in von Hippel-Lindau disease","volume":"12","author":"Asthagiri","year":"2010","journal-title":"Neuro Oncol."},{"issue":"2","key":"2023050411190401900_CIT0073","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/IAE.0b013e318030a290","article-title":"Intravitreal anti-vascular endothelial growth factor therapy with pegaptanib for advanced von Hippel-Lindau disease of the retina","volume":"27","author":"Dahr","year":"2007","journal-title":"Retina."},{"issue":"11","key":"2023050411190401900_CIT0074","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/j.ophtha.2008.04.033","article-title":"Intravitreal ranibizumab therapy for retinal capillary hemangioblastoma related to von Hippel-Lindau disease","volume":"115","author":"Wong","year":"2008","journal-title":"Ophthalmology."},{"issue":"12","key":"2023050411190401900_CIT0075","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1093\/annonc\/mdr011","article-title":"Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease","volume":"22","author":"Jonasch","year":"2011","journal-title":"Ann Oncol."},{"issue":"3","key":"2023050411190401900_CIT0076","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.oret.2016.10.007","article-title":"Systemic Sunitinib Malate treatment for advanced Juxtapapillary retinal Hemangioblastomas associated with von Hippel-Lindau disease","volume":"1","author":"Knickelbein","year":"2017","journal-title":"Ophthalmol Retina."},{"issue":"51","key":"2023050411190401900_CIT0077","doi-asserted-by":"crossref","first-page":"85306","DOI":"10.18632\/oncotarget.13301","article-title":"Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: a single-arm, prospective phase II clinical study from the PREDIR group","volume":"7","author":"Oudard","year":"2016","journal-title":"Oncotarget."},{"issue":"34","key":"2023050411190401900_CIT0078","doi-asserted-by":"crossref","first-page":"23390","DOI":"10.18632\/oncotarget.25171","article-title":"Pilot study of dovitinib in patients with von Hippel-Lindau disease","volume":"9","author":"Pili\u00e9","year":"2018","journal-title":"Oncotarget."},{"issue":"10","key":"2023050411190401900_CIT0079","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S1470-2045(18)30487-X","article-title":"Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial","volume":"19","author":"Jonasch","year":"2018","journal-title":"Lancet Oncol."},{"issue":"5","key":"2023050411190401900_CIT0080","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","article-title":"Inhibition of hypoxia-inducible factor-2\u03b1 in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis","volume":"27","author":"Choueiri","year":"2021","journal-title":"Nat Med."},{"issue":"9","key":"2023050411190401900_CIT0081","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.2017.74.2627","article-title":"Phase I\u00a0dose-escalation trial of PT2385, a first-in-class hypoxia-inducible Factor-2\u03b1 antagonist in patients with previously treated advanced clear cell renal cell carcinoma","volume":"36","author":"Courtney","year":"2018","journal-title":"J Clin Oncol."},{"issue":"1","key":"2023050411190401900_CIT0082","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10409238.2013.838205","article-title":"Transcriptional regulation by hypoxia inducible factors","volume":"49","author":"Dengler","year":"2014","journal-title":"Crit Rev Biochem Mol Biol."},{"issue":"32","key":"2023050411190401900_CIT0083","doi-asserted-by":"crossref","first-page":"22575","DOI":"10.1074\/jbc.M600288200","article-title":"Cell-specific regulation of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha stabilization and transactivation in a graded oxygen environment","volume":"281","author":"Bracken","year":"2006","journal-title":"J Biol Chem."},{"issue":"11","key":"2023050411190401900_CIT0084","doi-asserted-by":"crossref","first-page":"9899","DOI":"10.1074\/jbc.M312254200","article-title":"Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases","volume":"279","author":"Koivunen","year":"2004","journal-title":"J Biol Chem."},{"issue":"3","key":"2023050411190401900_CIT0085","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10689-019-00131-x","article-title":"The incidence of consecutive manifestations in Von Hippel-Lindau disease","volume":"18","author":"van\u00a0der\u00a0Horst-Schrivers","year":"2019","journal-title":"Fam Cancer."},{"issue":"16","key":"2023050411190401900_CIT0086","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1007\/s40265-021-01606-x","article-title":"Belzutifan: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs."},{"issue":"3","key":"2023050411190401900_CIT0087","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/cncr.33978","article-title":"Management recommendations for pancreatic manifestations of von Hippel-Lindau disease","volume":"128","author":"Laks","year":"2022","journal-title":"Cancer."},{"issue":"7627","key":"2023050411190401900_CIT0088","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature19796","article-title":"Targeting renal cell carcinoma with a HIF-2 antagonist","volume":"539","author":"Chen","year":"2016","journal-title":"Nature."},{"issue":"4","key":"2023050411190401900_CIT0089","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1158\/1078-0432.CCR-19-1459","article-title":"HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a First-in-Class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma","volume":"26","author":"Courtney","year":"2020","journal-title":"Clin Cancer Res."},{"issue":"601","key":"2023050411190401900_CIT0090","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aay0482","article-title":"HIF-independent synthetic lethality between CDK4\/6 inhibition and VHL loss across species","volume":"12","author":"Nicholson","year":"2019","journal-title":"Sci Signal."},{"issue":"22","key":"2023050411190401900_CIT0091","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa2110051","article-title":"Belzutifan, a potent HIF2\u03b1 inhibitor, in the pacak-zhuang syndrome","volume":"385","author":"Kamihara","year":"2021","journal-title":"N Engl J Med."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noac234\/47627994\/noac234.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/25\/5\/827\/50196098\/noac234.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/25\/5\/827\/50196098\/noac234.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T12:39:29Z","timestamp":1683203969000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/25\/5\/827\/6755426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,10]]},"references-count":91,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,10,10]]},"published-print":{"date-parts":[[2023,5,4]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noac234","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2022,10,10]]}}}